Aktis Oncology, Inc.
AKTS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002035832
In the last 90 days, Aktis Oncology, Inc. insiders filed 0 open-market purchases and 1 sale; 124 institutions reported holding it in 13F filings for Q3 2026, worth $716.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $901.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $258.6K in total
- 1
- 13F holdersQ3 2026, +15 vs. previous quarter
- 124
- 13F valueReported value at the end of Q3 2026
- $716.6M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q3 FY2026
- $3.90M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.43M
- Shares sold short
- Change
- +112.2K
- +2.6% vs. previous
- Days to cover
- 16.02
- At average daily volume
Superinvestors holding AKTS, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding AKTS at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aktis Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:05 PM ET | Sep 23 | 1 day | Czibere AkosChief Medical Officer | SSale | −12.5K | $20.69 | −$258.6K | −100.0%0 after | 2 lots10b5-1 |
| Jul 21, 2026 (view filing)8:50 PM ET | Jul 20 | 1 day | Herrmann KenDirector | SSale | −4.86K | $24.56 | −$119.3K | −100.0%0 after | 2 lots |
| Jul 20, 2026 (view filing)5:34 PM ET | Jul 17 | 3 days | Herrmann KenDirector | SSale | −3.06K | $25.21 | −$77.3K | −100.0%0 after | |
| Jul 10, 2026 (view filing)6:11 AM ET | Jul 8 | 2 days | Ron-Bigger ShulamitChief Operating Officer | SSale | −50.0K | $27.75 | −$1.39M | −100.0%0 after | 3 lots |
| Jul 10, 2026 (view filing)6:10 AM ET | Jul 8 | 2 days | Czibere AkosChief Medical Officer | SSale | −50.0K | $27.77 | −$1.39M | −100.0%0 after | 3 lots |
| Jan 14, 2026 (view filing)6:19 PM ET | Jan 12 | 2 days | Evnin Luke and 7 others10% Owner | PPurchase | +1.11M | $18.00 | +$20.0M | +12.2%10.3M after | Duplicate filing |
| Jan 14, 2026 (view filing)6:17 PM ET | Jan 12 | 2 days | Gadicke Ansbert and 2 others10% Owner | PPurchase | +1.11M | $18.00 | +$20.0M | +12.2%10.3M after | |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Foley ToddDirector, 10% Owner | PPurchase | +232.9K | $18.00 | +$4.19M | +5.8%4.24M after | |
| Jan 12, 2026 (view filing)8:28 PM ET | Jan 12 | Same day | Nodelman Oleg and 1 otherDirector | PPurchase | +2.22M | $18.00 | +$40.0M | New position347.3K after | 2 lots |
| Jan 12, 2026 (view filing)5:10 PM ET | Jan 12 | Same day | Vida Ventures II, LLC and 1 other10% Owner | PPurchase | +835.0K | $18.00 | +$15.0M | New position157.4K after | 2 lotsDuplicate filing |
Top 10 13F holders, Q3 2026
See all 124 holdersThe largest institutional positions in Aktis Oncology, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Oncology Impact Management LP | 4,835,872 | $94.2M | 7.25% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 4,824,469 | $93.9M | 4.62% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 3,343,827 | $65.1M | 11.92% | +273,608+8.9% | Added |
| T. Rowe Price Investment Management, Inc. | 3,333,026 | $64.9M | 0.05% | +1,281,579+62.5% | Added |
| BlackRock, Inc. | 2,780,745 | $54.1M | 0.00% | +502,387+22.1% | Added |
| RTW Investments, LP | 1,592,043 | $31.0M | 0.31% | 00.0% | Unchanged |
| Wellington Management Group LLP | 1,471,969 | $28.7M | 0.01% | −494,275−25.1% | Reduced |
| Price T Rowe Associates Inc | 1,184,617 | $23.1M | 0.00% | +421,118+55.2% | Added |
| Vanguard Capital Management LLC | 1,180,925 | $23.0M | 0.00% | +363,850+44.5% | Added |
| Eventide Asset Management, LLC | 1,065,000 | $20.7M | 0.29% | +558,000+110.1% | Added |
Holders of 5% or more of AKTS
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aktis Oncology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| MPM Bioventures 2018, L.P. | 13D | 19.30%10.3M shares | New | Jan 20, 20261 filing | Jan 20, 2026 | SEC |
| Eli Lilly & Co | 13D | 11.90%6.34M shares | New | Jan 15, 20261 filing | Jan 15, 2026 | SEC |
| VV Manager II, LLC | 13D | 10.90%5.83M shares | New | Jan 14, 20261 filing | Jan 14, 2026 | SEC |
| EcoR1 Capital, LLC | 13D | 9.10%4.86M shares | New | Jan 20, 20261 filing | Jan 20, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 6.20%3.33M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |